TEAM

MANAGEMENT
TEAM

Takahiro Iwamiya

Co-Founder / Co-CEO

Read more

Takahiro Iwamiya

Co-Founder / Co-CEO

  • Graduated from Tokyo Women’s Medical University with a Ph.D. in Medicine in March, 2014
  • From 2010, Taka worked on regeneration of the heart and cardiac fibroblasts at Tokyo Women’s Medical University’s Advanced Biomedical Sciences (TWIns)
  • From 2014, Taka led a research team to create organ tissues with fibroblasts at the Institutes for Advanced Biosciences, Keio University. Taka started to prepare for the launching of Metcela in that same year
  • As a co-founder at Metcela, Taka is responsible for R&D matters

Kenichi Nogami

Co-Founder / Co-CEO

Read more

Kenichi Nogami

Co-Founder / Co-CEO

  • Graduated from the University of Tsukuba with a B.A. in International Relations in March, 2008. Ken started the MBA program at UCLA Anderson School of Management in August, 2015 (later dropped out)
  • Began professional career as an investment banker at Sumitomo Mitsui Banking Corporation in 2008 and continued at Morgan Stanley from 2010, Ken cultivated expertise in M&A and equity financing for 6.5 years
  • Since 2014, Ken led the corporate development office at The RealReal Japan, while preparing to launch Metcela with Taka
  • As a co-founder at Metcela, Ken is responsible for all the business initiatives including financing, business model development, partnerships and clinical development strategies

ADVISORY BOARD

Phillip C. Yang, M.D.

Associate Professor of Medicine (Cardiovascular Medicine), Stanford University School of Medicine

Phillip C. Yang, M.D.

Associate Professor of Medicine (Cardiovascular Medicine), Stanford University School of Medicine

  • Directs the Cardiovascular Stem Cell Laboratory and Stanford Cardiothoracic MRI Program
  • Research interest focuses on translational effort of iPSC-derived small molecules for cardiovascular restoration
  • Received BAS and MA from Stanford University and M.D. from Yale University School of Medicine, and completed post-graduate training at UCLA and Stanford University Medical Centers

Fumiaki Ikeno, M.D.

Program Director (U.S.) Japan Biodesign, Stanford Biodesign, Medicine

Fumiaki Ikeno, M.D.

Program Director (U.S.) Japan Biodesign, Stanford Biodesign, Medicine

  • Currently serves as a Chief Medical Officer at Medventure Partners, Inc.
  • Works as a research associate of cardiovascular medicine at Stanford University where he is responsible for preclinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases
  • Visiting Professor at T-CReDO (Tsukuba Clinical Research & Development Organization) since 2019

Devang Thakor, Ph.D.

Founder and President, Anioplex, LLC

Devang Thakor, Ph.D.

Founder and President, Anioplex, LLC

  • President of Anioplex, LLC, a global strategy, business, and technical advisory firm serving startups, multinational corporations, venture capital firms and universities
  • Research expertise in regenerative medicine, stem cells, and gene therapy and biomaterials at Harvard Medical School, Kyoto University and UCLA
  • Ph.D in Biomedical Engineering from UCLA; currently studying law at Santa Clara University, with J.D. and California attorney license expected in 2020